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After nearly three decades of research in
many parts ofthe world, neurobehavioral
toxicity is nowacknowledged as asignificant
outcome ofchemical exposure. In contrast
to the view prevailing even in the recent
past, many observers now concede that its
health and economic costs may exceed even
those ofcancer, the prototype for risk assess-
ment, by substantial amounts. This new
perspective has been accompanied by a
surge ofefforts designed to promote effec-
tive test methods, to explore the responsible
mechanisms, to design applicable risk assess-
ment procedures, and to determine the
consequent policyimplications (1,2).
The process ofrecognition did not pro-
ceed as smoothly as expected, given the reso-
nant scientific foundations provided by the
behavioral neurosciences. One of these,
behavioral pharmacology, the discipline that
emerged in the 1950s in response to the
introduction ofchemotherapy for psycho-
logical disorders, provided a readily adapt-
able technology for exploring adverse
effects. Workplace exposure criteria, such
as threshold limit values (TLVs), had long
relied on behavioral criteria such as work
efficiency and alertness to danger to infer
hazard. Perhaps the problem lay in how
easily misunderstandings can arise about the
definition and measurement ofbehavior.
Although the discipline has generated
an abundant literature and established a
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robust scientific footing, translating such
efforts into policy decisions remains per-
plexing, mainly because of the difficulties
posed by how to express them in risk
terms. The conventional prototype for risk
assessment is cancer, but numerous dissim-
ilarities between neurobehavioral toxicity
and carcinogenesis render it a rather imper-
fect model. Because behavior is often cited
as the integrated product ofa highly com-
plex system, with numerous modes of
expression, it should come as no surprise
that it maybe altered in equallydiverse ways
by xenobiotic influences and that the
significance of any but the most blatant
behavioral change eludes simplistic measures
and interpretation.
After all, behavior is a dynamic and
plastic phenomenon. It would be deceptive
to compare it to functions that are much
more rigid and deterministic such as those
of the cardiovascular system. Scientists
unaccustomed to phenomena as malleable
as behavior sometimes find it difficult to
grasp both its essential lawfulness and the
degree to which, concurrently, it may
undergo critical modifications without dis-
playing any overt abnormalities. Some con-
sider behavioral changes to be analogous to
alterations in software which, by proper
reprogramming, may be overcome without
major difficulties. Others may claim that
behavioral deficiencies attributed, for exam-
ple, to elevated exposure to metals, are more
likely the product ofdeficiencies in social
conditions. Such claims tend to erode when
confronted jointly by data from properly
conducted animal research and from epi-
demiological studies that deliberately and
carefully weigh and balance the influence of
potentially confounding social variables.
Several ofthe joint chapters and indIvidual
papers reviewthese issues.
A brpad, permeating issue derives
from one ofthe original aims of SGOM-
SEC: to make its contributions pertinent
to countries lacking advanced industrial
economies and resources. Chemicals and
chemical production facilities tend to be
transferred to such countries without an
accompanying transfer ofthe technology of
toxicology and environmental health sci-
ence. This discrepancy results in unsafe con-
trol practices, excessive exposure levels, and,
ultimately, mass chemical disasters. SGOM-
SEC 11 strove to confront this issue by
describing a range ofmethods from the rela-
tively simple to the rather complex and by
illustrating the different contexts in which
different methods are appropriate. But
even in advanced industrial societies, policy
analysts, regulators, and others with deci-
sion-making responsibilities are confronted
with irksome questions about neurobehav-
ioral toxicity. In that arena, the challenges
range from how to determine whether the
potential for neurotoxicity exists to how to
translate such potential into policy.
SGOMSEC 11 was also designed to
learn from the history ofneurobehavioral
toxicology. It sometimes proved difficult to
convince toxicologists from other specialties
and policy makers that even substances
already dispersed in the human environ-
ment require careful evaluation of their
neurobehavioral toxicity, despite no cogent
evidence of adverse effects at environ-
mental levels. Once a substance is widely
distributed in the communal, or even the
industrial environment, barriers to its
removal are riveted in place. Especially if
the arguments for its control are based, not
on immediate threats to life but on a less
tangible behavioral metric, inertia exerts a
potent force. The arguments for premarket
testing for neurobehavioral toxicity flow
from such experiences.
The Choice of a Focus
on Behavior
The adjective neurobehavioral is commonly
applied because the nervous system deter-
mines the contours ofits ultimate product,
behavior. Any measure of nervous system
status or function incurs immense complexi-
ties. Behavior's credentials as a valid toxicity
index are often questioned because its deter-
minants converge from many paths. The
consequences of a specific neurochemical
aberration such as a shift in receptordensity,
for example, may b'e expressed behaviorally
in almost limitless ways depending on the
specific end points and indices chosen for
measurement and the constitutional capaci-
ties and behavioral history ofthe individual
organism. Consider the numerous behaviors
linked to the neurotransmitter dopamine: a
variety ofcognitive functions, mediation of
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reinforcement processes, tremor and other
indices of motor function, sexual perfor-
mance and motivation, and even species-
specific behaviors. Naturally, the most
appealing situation is one in which neuro-
chemical findings could be correlated with
behavioral data, but most behaviors are
joined to more than one neurotransmitter
system and embrace more than a single
brain structure. Such multiple connections
explain why neurochemistry, morphology,
and even electrophysiology would nor-
mally be introduced only at the later stages
ofassessment.
Because it arises from multiple sources,
behavior might be viewed as a confusing
index oftoxicity. That potential for confu-
sion, however, is also an argument in its
favor. Ifit is subject to such a wide array of
influences, the argument goes, it can then
serve as an apical tool for testing general
toxicity. Ifsuch evidence emerges, more
specific behavioral or other measures can be
applied to narrow the contributing variables
or mechanisms. The opposing argument
claims that, because behavior reflects the
integration ofa highly redundant system in
which compensatory mechanisms may
obscure a deficit in anyparticular functional
domain, it is not a sensitive measure of
adverse effects in all circumstances.
Both arguments, despite their appar-
ently conflicting stances, invoke equivalent
conclusions: toxic potential should be
assessed by choosing behavioral end points
that offer the greatest breadth and precision
ofinformation. Itshould be recognized that
the appeal ofsimplicity and economy may
prove deceptive and even costly if they
merely multiply the intrinsic ambiguities of
risk assessment. SGOMSEC 11 aimed to
deal explicitly with such supramethodolog-
ical issues while offering critical reviews of
theprevailing approaches.
The final design of SGOMSEC 11
divided the issues into four sections: neu-
robehavioral toxicity in humans, neurobe-
havioral toxicity in animals, model agents,
and risk assessment. Anyone familiar with
the discipline appreciates that these rubrics
do not describe fixed boundaries, but con-
venient dassifications. In fact, the extensive
overlap between these categories proved to
be an advantage because members of one
group could be enlisted, in preparing the
joint report, to assist another group when
their special qualifications were required.
The outline belowprovides a list oftop-
ics for which individual papers were com-
missioned. Each of the participants was
asked to feature three points: How did we
get to the current status ofthe topic? How
can we relate it to risk assessment? 'What
methodological advances should we seek to




This section was designed to explicate the
ways in which information about hazard
and risk might be procured from human
populations. In some past instances, this
information came from clinical observa-
tions, usually on the basis ofextreme expo-
sure levels. The current mode ofdefining
risks depends mostly on the use ofpsycho-
logical test instruments, but questions
remain about their relevance and suitability.
Clinical Data as aBasisfor
HazardIdentification
Many of the neurobehavioral toxicants
now viewed as hazardous to humans origi-
nally earned recognition through the obser-
vations ofclinicians. These toxicants came
to their attention because of signs and
symptoms overtly expressed by patients.
What are the lessons to be learned from this
history? What tools should clinicians be pre-
pared to deploy in such instances? Is hazard
identification the only role fulfilled by dini-
cal observations? Is there a series ofsteps,
undertaken in aclinical context, that might
lead to a firmer basis for identifying and
estimating risk once such observations are
validated? How can dinical observations be
translated efficiently into epidemiological
studies? Can a useful guide be designed for
doing so? Is a tiered strategy, that is, one
that builds systematically from one set of
observations to another more complex set
the most appropriate one to adopt, or does
such staging ofquestions tend to delay the
risk assessment process? Are there useful
examples ofsuch aprogression?
DesigningandValidatingTestBatteries
Beginning in about the early 1970s,
psychological test batteries began to be
applied to the definition and assessment of
adverse consequences stemming from
exposure to central nervous system-active
agents such as volatile organic solvents. By
now, a plethora oftest collections has pen-
etrated the literature. Although these bat-
teries possess many elements in common,
theyalso diverge in philosophy and design.
What are the strengths and weaknesses
ofthe present array ofbatteries? How might
they be improved while maintaining their
advantages ofease ofuse and broad accep-
tance? Would they still be suitable for criti-
cal applications in less advanced countries?
What about their suitability for longitudi-
nal assessments? Howwell do they evaluate
sensory and motor function?
The most widely adopted batteries are
anchored in diagnosis. Their roots lie in neu-
ropsychology and the assessment ofbrain
damage and psychopathology. Should other
approaches be considered? Test batteries are
generally constructed to use briefsamples of
behavior to screen for adverse effects in pop-
ulations such as workers. Is the breadth of
test items in the typical battery a problem?
What are the advantages and disadvantages
of adopting a more intense focus? This
approach might be used for pilot and astro-
naut selection or to represent translations
from complex performance in animals. Do




A problem now looming for neuropsychol-
ogy and neurobehavioral toxicology is the
collection ofquasi-clinical, often vaguely
defined syndromes labeled as Multiple
Chemical Sensitivity, Sick Building Syn-
drome, and Chronic Fatigue Syndrome. All
are reflections ofpatient complaints lacking
consistent objective verification such as that
provided, say, by dinical chemistry profiles.
As a result, many clinicians and biomedical
scientists tend to view such complaints
skeptically, or find themselves unable to
propose any course ofaction. Does part of
the problem arise from the emphasis by
neuropsychology on diagnosis rather than
on functional variables or on labeling of
deficits rather than on determinations of
how effectively the individual functions in
his or her environment? How can such data
be collected or synthesized or estimated?
Are there especially suitable experimental
designs for such questions, such as single-
subject designs? What alternatives to cur-
rent assessment procedures hold promise?
Would they be suitable for longitudinal
evaluations such as those that might become
necessary for monitoring the aftermath ofa
poisoningepisode?
Developmental Neurotoxicity
The period ofearly brain development is a
precarious stage because insults inflicted
during this time seem to ramify in many
directions, often first becoming perceptible
only after reaching a particular epoch ofthe
life cycle. As aconsequence, afull evaluation
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of the neurotoxic impact of prenatal and
neonatal exposure virtually demands longi-
tudinal investigations for definitive answers.
What are the essential elements of such
designs? Which features are absolutely
indispensable? What are the most serious
confounders? Can these kinds of studies
somehow be streamlined? To what extent
can cross-sectional studies serve as surro-
gates or, at least, pointers? Can the proce-
dures of animal testing, which do not
require the same degree of compensation






Evaluations in laboratory animals fulfill
two purposes. First, for new chemicals,
these evaluations should make it possible to
determine whether an agent presents a
significant hazard. They also allow explo-
ration of the potential dimensions of the
hazard. Finally, they may make it possible
to distill quantitative risk estimates for
humans, in parallel with the way in which
bioassay data are used in cancer risk assess-
ment. Tumors, however, are presumed to
reflect processes that will occur in human
hosts. Neurobehavioral deficits in animals
are less directly translatable into human
functions. What should be the role of ani-
mal research and in what ways can it serve
the ultimate purpose ofrisk assessment?
Many critics attack the validity of
extrapolating behavioral data from animals
to humans. Indeed, behavior seems to be
highly species-specific and exquisitely
adapted to the organism's and its species
survival needs. Although such critics grant
the universality ofthe genetic code, they are
less willing to grant the universality ofthe
neural mechanisms governing the operation
of nervous systems in different species. In
this framework, humans are viewed as
beyond extrapolation, with human behav-
ior accorded the status of some emergent
phenomenon disconnected from the brain
structures theyshare with other species.
No one denies that the structural differ-
ences-between rodent and human brains
and the differences in behavioral repertoires
vitiate any facile and superficial extrapola-
tions. But the underlying functional mecha-
nisms ofthe brain, and their expression in
behavior, are shared by these organisms.
Rat behavior can be used as a model of
human behavior ifa model is defined as a
system possessing essentially the same func-
tional properties as the one it simulates,
except in a simplified version. Deficits in
human behavior ascribed to neurotoxicants
tend to manifest themselves in fundamen-
tal functional properties shared with other
species. Labels such as attention, emotional
responsivity, sensory processing, motor
coordination, learning disabilities, and oth-
ers are not specifically human properties of
behavior. Human language is distinctive,
ofcourse, but its acquisition displays a pat-
tern common to many other behaviors that
follow a developmental sequence in which
environmental and constitutional variables
merge continuously. The primary source of
confidence in the power of extrapolation
though is a body offindings that supports
the congruence of human and animal
responses to neurotoxicants.
Natural Populadtions asSentinels
Safety evaluation ofenvironmental chemi-
cals has been broadened to include ecologi-
cal risk assessment. The U.S. EPA's Science
Advisory Board report, Reducing Risk (3),
is one instance ofthis growing appreciation,
but the impact ofchemical pollution on nat-
ural populations rose to a subject ofwide-
spread concern after Rachel Carson's seminal
book (4). We now acknowledge that a
major element in this impact derives from
disruptions in behavior; one example is a
reported diminution ofnest attentiveness by
birds in the Great Lakes. What are the indi-
cators that up to now have proven useful in
natural populations? In which directions
should improvement in these methods be
pointed? What is the extent ofconcordance
between such observations and human
health effects or with laboratory animal
studies? How can ecological observations be
converted into the kinds ofquantified vari-
ables characteristic oflaboratory experi-
mentswithout losing essential information?
LaboratoryApproaches: Scopeand
SelectionofEndPoints
For new chemicals, laboratory assays pro-
vide the first filtering stage for potential
toxicity. Currently, a standardized set of
observations, such as a functional observa-
tion battery (FOB), is used to probe for
neurobehavioral effects. Certain regulatory
bodies have also required measures of
motor activity, perhaps accompanied by
neuropathology at this stage. These criteria
are acknowledged as broadly suggestive
rather than as definitive, especially at the
point when dose-response modeling enters
the risk assessment process.
For many purposes, the clinical exami-
nation, as in humans, will represent the
first initiative, and often the first clues that
a neurotoxic agent has appeared on the
scene. Can a standardized protocol be
designed that will prove feasible, in settings
lacking other resources, and sensitive as
well? How should such a protocol be
modified for examinations in the field, as
forwild animal populations?
Ifa more comprehensive evaluation is
sought, what should be its constituents?
What considerations should guide the selec-
tion of experimental parameters? What
research should be conducted to help refine
such a process? What constraints are
imposed by the extrapolation issue? How
vital is it to assure that observations in ani-
mals reflect analogous functions in humans?
Is it more important to select end points
that reflect the functional capacities ofthe
particular species?
What economies ofapproach are feasi-
ble when resources are limited? Does the
strategy of tiering, in which assessments
branch to increasingly specific and complex
assessments, make sense in such situations?
How might low cost and sensitivity be
combined? What should be the priorities
in such a process?
Developmental Neurotoxicants
Exposure to chemicals during early develop-
ment often inflicts toxic consequences rather
different from the consequences inflicted on
mature nervous systems. In addition to the
modes ofdamage, however, differences arise
in how the damage may be expressed. For
example, it may emerge only after a pro-
longed latency, perhaps as late as senescence.
Or, it may appear in different guises at dif-
ferent phases ofthe life cycle. U.S. EPA and
other regulatory bodies have prescribed
standardized protocols for assessing devel-
opmental neurotoxicity. Do these protocols
offer support for a comprehensive, quanti-
tative risk assessment? If not, how should
they be modified? Are they efficiently
designed and are some elements ofthese
protocols possibly redundant? For example,
does the absence offunctional impairment
at a particular exposure level preclude mor-
phological aberrations at that level? Or
nust all pogential-sources ofinformnation
be examined?
Model Agents
The agents discussed in this section offer
cogent history lessons. Organic solvents
and chlorinated hydrocarbons were widely
used for many years without mnuch concern
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over their possibly adverse effects. By the
time these properties had been identified in
a painfully slow process, the agents had
already pervaded the environment or had
become so essential that their removal, even
iftechnically possible, became impractical.
Methylmercury and lead had been recog-
nized as neurotoxicants long before their
current prominence, but an appreciation of
their more abstruse expression at low expo-
sure levels required an abundance of
resources and investigator dedication in the
face ofsometimes monumental skepticism.
Current neurobehavioral toxicology
largely owes its standing to these agents
because they exemplify the power ofbehav-
ioral end points. We asked the participants
to review what we have learned from inves-
tigations ofagents now established as pro-
totypes. For example, would a retrospective
analysis ofthe literature built around such
model agents provide guidance for how to
approach new agents? What would have
been the most appropriate testing schemes
and toxic end points and which assessment
strategy would have yielded maximum
information at the least cost?
Those enumerated below all owe their
original identification as neurobehavioral
toxicants to observations in humans, typi-
cally at high doses. What might have been
the outcome had these agents first been
examined as new chemicals? Which end-
points would have proven to be sensitive?
To what degree, for each agent, have we
observed a convergence between progress in
human and animal research?
Lead
Lead was recognized as a hazard even in
antiquity but was frequently ignored.
Only with the accumulating, incremental
evidence provided by methodological
refinements did we progress to the present
situation. The current Centers for Disease
Control (CDC) guidelines denote blood
levels above 10 pg/dl as a potential index of
excessive exposure-a sharp fall from the
standards prevailing only a short time ago.
Animal and human data show periods both
ofconvergence and divergence but, on the
whole, took parallel paths. Attaining con-
vergence, the current situation, required
improvements in both sets ofmethodolo-
gies, but the animal data proved critical
because ofthe criticisms aimed at the epi-
demiological studies. In essence, investiga-
tors learned how to ask the appropriate
questions. It was not a process that would
have succeeded without the inevitable but
instructive blunders.
Methylmercury
Not long ago, methylmercury was viewed
only as a hazardous chemical confined to
narrow purposes and distribution. A chain
ofmass chemical disasters gradually altered
this view, but the extrapolation from mass
disasters to broad implications for public
health came slowly. On the basis ofknowl-
edge acquired from these disasters, 26
states in the United States have posted fish
advisories. Animal research contributed
significantly to our understanding of the
underlying mechanisms oftoxicity, but the
risk issues are still being played out, pri-
marily with the human disaster data. How
has animal research illuminated the human
risk perspective? What has it taught about
the approach to unevaluated chemicals?
What lessons should be drawn about the
longitudinal monitoring ofhuman popula-




Compounds ranging from dichloro-
diphenyltrichloroethane (DDT) to 2,4-
dichlorophenoxyacetic acid (2,4-D) to the
polychlorinated biphenyls (PCBs) to
2,3,7,8-tetrachlorobiphenyl-p-dioxin
(TCDD) have been implicated in neuro-
toxicity. Especially for the last two classes
ofchemicals, recognition oftheir potential
neurotoxic properties emerged only gradu-
ally, perhaps because it was submerged by
concerns about carcinogenicity. What is the
current perspective about the health risks
ofthese compounds, and what lessons does
its evolution provide for how other classes
of chemicals should be examined? Such
substances are also now implicated as envi-
ronmental estrogens with a new spectrum
ofneurobehavioral issues to address, some
ofwhich may even be lurking in data we
alreadypossess.
Solvents
Volatile organic solvents became an early
focus ofhuman neurobehavioral toxicology.
Their neurotoxic properties have always
been recognized, even in setting exposure
standards in the workplace. Wider recogni-
tion ofthese properties, especially in the
absence ofgross dysfunction, is attributable
to the application ofpsychological testing
methods. Because methodological advances
moved in parallel with improvements in
study design, the solvents literature has
provided guidance for similar questions.
The evolution ofthis research area to its
current state should offer lessons on how to
cope with related issues such as those stem-
ming from chemical sensitivity syndromes.
As with lead, animal models came on the
scene only after solvent neurotoxicity had
been well established. The same degree of
parallelism seen with lead has yet to be
achieved and awaits the application of
equally sensitive behavioral criteria.
Quantification, Modeling,
and Definition of Risk
The ultimate goal ofneurobehavioral toxi-
cology, apart from its inherent contribu-
tions to basic science, is formulating risk.
Although, by tradition, toxicity data are
transformed into values such as NOAELs,
this is simply a regulatory convenience
rather than a risk assessment. The conver-
sion ofneurobehavioral data into quantita-
tive risk assessments presents numerous
challenges. Cancer risk assessment, the pro-
totype, is based on premises that cannot be
applied to neurobehavioral toxicity. Among
these are the assumption ofa unitary bio-
logical process, cumulative dose as a valid
exposure parameter, and the irrelevance of




Another legacy ofthe cancer risk model is its
dependence on quantal data. Such measures
are easier to handle for risks expressed in
probabilistic terms, but most neurobehav-
ioral measures are continuous rather than
discrete. One result ofthis disparity is that
risk for systemic outcomes is typically
framed in terms such as NOAELs. Further-
more, many effects are graded over time, so
that they present features best expressed,
perhaps, as 3-dimensional surfaces. What are
possible models for expressing risks based on
such graded outcome measures? Do they
hold implications for experimental design
such as choices between number ofdose lev-
els and number ofobservations at each dose?
How should they reflect repeated measures
on the same subjects? Are there examples
from thecurrendyavailable literature?
ChoosingEndPoints
Unlike the model ofcancer, neurobehav-
ioral toxicology is compelled to rely on
several different types of measures as
guidance for risk estimates. Forexample, the
U.S. EPA has requested data from a FOB,
motor activity, schedule-controlled operant
behavior, and neuropathology to help it for-
mulate the health risks of exposure to
volatile organic solvents. Even pathology,
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which in the past constituted the primary
criterion oftoxicity, is inadequate by itself.
Furthermore, even a single criterion, such
as schedule-controlled operant behavior,
itself comprises multiple measures. Which
measures derived from such techniques
might be suitable for guiding the risk
assessment process?
A unique assortment of questions is
posed by developmental neurotoxicity
because the process ofdevelopment itself
offers inherent enigmas. Species extrapola-
tion in this context, despite fundamental
commonalities among species, poses an
additional layer ofuncertainty upon those
already confronting risk evaluations based
on species comparisons. Is the prevailing
strategy adequate for even gross prediction
or do its deficiencies herald further errors
or even disasters?
Neurobehavioral Epidemiology
How do neurobehavioral end points coin-
cidewith the requirements ofepidemiology?
Rather than cases, for example, the data may
consist ofdose-effect relationships in which
the effect may be expressed as alterations in
a spectrum ofdeficits, or, because ofindi-
vidual patterns ofsusceptibility, individuals
may differ in their relative responsiveness to
different end points. What would be an




Most observers recognize that, barring
rejection ofan agent at the earliest stage of
risk assessment, a broad but necessarily
superficial appraisal ofpotential neurobe-
havioral toxicity may be insufficient for
quantitative risk assessment or even for
identifying critical end points that are not
easily appraised with simpler techniques.
Under what conditions should a superficial
appraisal be relied upon to formulate risk?
Assume that further investigations beyond
the simplest may have to be conducted.
Can a cogent design for a sequential strat-
egy be formulated? What are satisfactory
starting and stopping points? One model
ofa quasi-tiered approach is the assessment
ofdevelopmental neurotoxicity, a model
imposed simply by the inability to reach
definitive conclusions about the impact of
exposure at one particular age from results
determined at another age. What should be
the major decision points in evaluations not
aimed at developmental questions or in
evaluations ofdevelopmental toxicity? Is it
more efficient to begin with the later deci-
sion points than to proceed, say, from
simple to complex in several stages? That is,
would the later decision points embody, as
well, the earlier ones? Are there decision
rules that can be constructed to guide such
a process? Can decision nodes be estab-
lished at which certain paths can be taken
for more definitive conclusions?
Tiered testing schemes generally proceed
from simple to complex criteria. This direc-
tion generally implies corresponding dimen-
sions such as from cheap to expensive, from
crude to sensitive, from high-dose to low-
dose effects, from acute to chronic effects,
from adult exposure to developmental
toxicity, from hazard identification to quan-
titative risk assessment. Such progressions
reveal where the problem lies in a tiered
testing approach: Ifmerely the absence of
toxicity in tier 1 procedures is legally
required for approval of substances that
may invade the environment and expose
humans and animals, new substances will
be tested by relatively simple and insensi-
tive tests following acute high-dose admin-
istration in adult animals. Would such a
strategy be adequate to offer protection
against the recurrence ofsituations such as
those described under Model Systems?
Will more scientific battles have to be
fought in 10 years to prompt an assessment
of the neurobehavioral toxicity of sub-
stances introduced today?
Summary
Neurobehavioral toxicology is now estab-
lished as a core discipline of the envi-
ronmental health sciences. Despite its
recognized scientific prowess, stemming
from its deep roots in psychology and neu-
roscience and its acknowledged successes, it
faces additional demands and challenges.
The latter, in fact, are a product of its
achievements because success at one level
leads to new and higher expectations. Now
the discipline is counted upon to provide
more definitive and extensive risk assess-
ments than in the past. These newdemands
are the basis for the appraisals presented in
the SGOMSEC 11 workshop. They extend
beyond what would be offered in a primer
ofmethodology. Instead, these appraisals
are framed as issues into which what are
usually construed as methodologies have
been embedded.
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